Scinai Immunotherapeutics Ltd. Sponsored Adr (SCNI) has released an update.
Scinai Immunotherapeutics Ltd. is pioneering advancements in dermatological drug development by focusing on inflammatory markers, particularly IL-17, which plays a critical role in psoriasis pathophysiology. Psoriasis, a systemic chronic inflammatory disorder affecting a significant portion of the population, leads to various comorbid diseases, significantly impairing life quality. The company’s research, presented at the 5th DDDS Europe, highlights the complex interplay of immune cells in psoriasis and underscores the potential for targeted therapies.
For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.
